Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorABOU-HAMDAN, M
dc.contributor.authorSALEH, R
dc.contributor.authorMANI, S
dc.contributor.authorDOURNAUD, P
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorMETIFIOT, Mathieu
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBLONDOT, Marie-Lise
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorANDREOLA, Marie-Aline
dc.contributor.authorABDEL-SATER, F
dc.contributor.authorDE REGGI, M
dc.contributor.authorGRESSENS, P
dc.contributor.authorLAFORGE, M
dc.date.accessioned2023-10-17T13:52:56Z
dc.date.available2023-10-17T13:52:56Z
dc.date.issued2023-02-08
dc.identifier.issn2045-2322en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/184471
dc.description.abstractEnSARS-CoV-2 interacts with cellular cholesterol during many stages of its replication cycle. Pantethine was reported to reduce total cholesterol levels and fatty acid synthesis and potentially alter different processes that might be involved in the SARS-CoV-2 replication cycle. Here, we explored the potential antiviral effects of pantethine in two in vitro experimental models of SARS-CoV-2 infection, in Vero E6 cells and in Calu-3a cells. Pantethine reduced the infection of cells by SARS-CoV-2 in both preinfection and postinfection treatment regimens. Accordingly, cellular expression of the viral spike and nucleocapsid proteins was substantially reduced, and we observed a significant reduction in viral copy numbers in the supernatant of cells treated with pantethine. In addition, pantethine inhibited the infection-induced increase in TMPRSS2 and HECT E3 ligase expression in infected cells as well as the increase in antiviral interferon-beta response and inflammatory gene expression in Calu-3a cells. Our results demonstrate that pantethine, which is well tolerated in humans, was very effective in controlling SARS-CoV-2 infection and might represent a new therapeutic drug that can be repurposed for the prevention or treatment of COVID-19 and long COVID syndrome.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAnimals
dc.subject.enChlorocebus aethiops
dc.subject.enHumans
dc.subject.enSARS-CoV-2
dc.subject.enAntiviral Agents
dc.subject.enCOVID-19
dc.subject.enPost-Acute COVID-19 Syndrome
dc.subject.enVirus Replication
dc.subject.enVero Cells
dc.title.enPotential antiviral effects of pantethine against SARS-CoV-2.
dc.title.alternativeSci Repen_US
dc.typeArticle de revueen_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed36754974en_US
bordeaux.journalScientific Reportsen_US
bordeaux.page2237en_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue1en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scientific%20Reports&rft.date=2023-02-08&rft.volume=13&rft.issue=1&rft.spage=2237&rft.epage=2237&rft.eissn=2045-2322&rft.issn=2045-2322&rft.au=ABOU-HAMDAN,%20M&SALEH,%20R&MANI,%20S&DOURNAUD,%20P&METIFIOT,%20Mathieu&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée